Filament Health is a global extraction and drug discovery company. The company have a deep natural psychedelics IP portfolio and are led by an accomplished botanical extraction management team.
The company’s aim is to make safe, natural psychedelics accessible to anyone who needs them by unlocking their healing potential through hard extraction and drug discovery science.
They possess a Health Canada psilocybin Dealer’s License as well as in-house GMP manufacturing capabilities at their R&D facility on the British Columbia Institute of Technology campus.
Filament aims to discover and extract naturally occurring psychedelic compounds and make these drugs available to people with mental disorders. At present, the company are preparing to conducted trials on their proprietary psilocybin formulation PEX010.
“Psychedelic Medicines Naturally Derived.”
On June 24th 2021, Filament Health raised a total of C$5,000,000 at Initial Public Offering (IPO) on Canadas NEO Exchange. Valuation at IPO was $60,000.
- Filament Health is the First Public Company to be Issued a Patent for Extraction of Natural Psilocybin (Cision, August 2021)
- Exclusively-Natural Psychedelic Pharma Company, Filament Health, Lists on the NEO Exchange (Business Wire, June 2021)
B2B Manufacturing Pharmaceutical Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates